Drug Database
YY

YY-3130 (YY 3130 / YY3130)

✓ Approved

YuYu Pharma · Small Molecule · Small Molecule

What is YY-3130?

YY-3130 is a small molecule developed by YuYu Pharma. It is approved for therapeutic indications via unknown.

Drug Profile

Brand NamesYY 3130, YY3130
CompanyYuYu Pharma
Drug ClassSmall Molecule
RouteUnknown
StatusApproved

Therapeutic Indications

YY-3130 is developed for 1 unique indication across 1 therapeutic area.

Therapeutic AreaConditionPhase
Metabolism and nutrition disordersHypercholesterolaemia✓ Approved

Related Research Articles

PubMedCatalysis science & technology2026-11-11

Highly active earth-abundant ammonia cracking catalysts using long chain hydrocarbon stabilised colloidal nanoparticles.

Mahin Julien J, El-Kadi Joseph J, Torrente-Murciano Laura L

In this work, we report the synthesis of highly active non-noble metal catalysts with controlled nanoparticle size and dispersion through a new catalyst preparation strategy, combining the continuous-flow synthesis of size-controlled Fe, Co and Ni nanoparticles by thermal decomposition of zero-valent precursors with their direct impregnation via the so-called colloidal incipient wetness impregnation (CIWI). The use of long-chain hydrocarbon ligands provides not only size control and colloidal stability at high nanoparticle concentration but also the synergetic simultaneous removal and metal reduction at low temperatures. Indeed, we demonstrate that the removal of these ligands is catalysed by Co and Ni particles, enabling their simultaneous reduction at lower temperatures and thus, avoiding their agglomeration. This combination of controlled nanoparticle synthesis, high-concentration processing and in situ self-cleaning provides a route to size control that is difficult to access by conventional incipient wetness impregnation. The flexibility of CIWI further enables systematic investigation of nanoparticle size-activity relationships independently of support effects. Applied to ammonia decomposition, Ni/CeO2 exhibits a pronounced size dependence, with 2.4 nm Ni nanoparticles delivering an activity of 3130 molNH3 molmetal -1 s-1 at 500 °C, ranking among the most active earth-abundant catalysts reported to date and approaching the performance of state-of-the-art Ru-based systems. The CIWI therefore provides a versatile platform for designing highly active, size-controlled non-noble metal catalysts and is broadly applicable to other metal-support combinations and catalytic reactions.

PubMedFrontiers in medicine2026-11-08

Enteroendocrine signaling in irritable bowel syndrome: beyond cell counts toward stimulus-responsive physiological profiling.

Han Jiayi J, Lang Yixuan Y, Yao Kangmeng K, Mi Jia J

Meals are a major symptom trigger in irritable bowel syndrome (IBS), yet the endocrine steps linking luminal nutrients to pain, bloating, urgency, and altered bowel habits remain poorly defined. Early studies relied heavily on mucosal enteroendocrine cell (EEC) counts. Those observations remain informative, particularly in post-infectious IBS, but findings vary with intestinal site, bowel-habit phenotype, staining, and morphometry, and cell abundance does not measure secretory function. Human meal-challenge studies distinguish circulating concentrations from stimulus-evoked responses. In IBS with diarrhea, higher fasting and fed plasma 5-hydroxytryptamine (serotonin, 5-HT) may reflect altered handling more than a uniformly exaggerated postprandial response, whereas IBS with constipation can show impaired stimulus-evoked release. Cholecystokinin, peptide YY, motilin, ghrelin, and related peptides also vary with sex, bowel habit, and visceral sensitivity. Recent human organoid and transcriptomic studies identify distinct nutrient-sensing programs among EEC subtypes and provide a cellular framework for this heterogeneity. We integrate these findings across luminal sensing, secretion, metabolism, receptor responsiveness, and motor or sensory output. The evidence does not support a single IBS endocrine signature. Standardized nutrient challenges linked to serial hormone measurements, mucosal molecular data, and objective physiological readouts are more likely to yield reproducible and clinically testable response patterns.

PubMedPharmacology, biochemistry, and behavior2026-11-01

Corni Fructus water extract relieves depressive behaviors by reducing oxidative stress and neuroinflammation as well as modulating gut microbiota.

Hui Heping H, Liu Ziyang Z, Mao Haoji H, Chen Lin L et al.

Depression is a global public health concern with limited therapies. Traditional Chinese medicines are attractive for safety and multi-target actions. Corni Fructus water extract (CFWE) is a candidate, but its mechanisms and the main active ingredients remain unclear. A chronic unpredictable mild stress (CUMS) mouse model was established and given CFWE intervention. Depressive-like behaviors were evaluated by sucrose preference test (SPT), tail suspension test (TST), and open field test (OFT). Hippocampal histopathology was examined using H&E staining. Inflammatory and oxidative stress-related factors in the hippocampus and serum were detected using ELISA kits. RT-qPCR and Western blot measured Nrf2/HO-1 and IκBα/NF-κB pathway components. Gut microbiota and short-chain fatty acids (SCFAs) were analyzed via 16S rRNA sequencing and GC-MS. LC-MS determined the major chemical constituents of CFWE. CFWE significantly alleviated CUMS-induced depressive-like phenotypes, including preserved body weight, reduced immobility time in TST, increased sucrose preference, and greater central distance in OFT (P < 0.05 or P < 0.01). It also increased neuronal survival in hippocampal CA1/CA3 (P < 0.01), lowered pro-inflammatory cytokines (IL-1β, IL-6, TNF-α) and MDA (P < 0.05) in serum and hippocampus, and elevated CAT and SOD activities dose-dependently (P < 0.05). Mechanistically, CFWE upregulated Nrf2, HO-1, and IκBα expression, while downregulating phosphorylated NF-κB p65 expression (P < 0.05). It also restored gut microbial diversity (P < 0.05), promoted beneficial taxa (Muribaculaceae and Lactobacillus), enhanced SCFAs production, and elevated peripheral peptide YY (PYY). LC-MS analysis revealed that the main active constituents in CFWE were terpenoid glycosides, flavonoid glycosides, and organic oxygen compounds. The antidepressant-like effects of CFWE might involve activation of the Nrf2/HO-1 antioxidant pathway, suppression of the IκBα/NF-κB inflammatory response, and modulation of gut microbiota composition and SCFA metabolism, while PYY might serve as a candidate mediator in gut-brain communication.

PubMedNutrients2026-10-27

The Microbiota-Gut-Brain Axis in Obesity: Inflammation, Appetite Dysregulation, and Feeding Behavior.

Sandoval-Valenzuela Camila C, Pacheco Rodrigo R

Obesity is increasingly recognized as a disorder of bidirectional communication among the gut microbiota, immune system, and neural circuits controlling energy balance and feeding behavior. This review examines the associations and potential mechanistic links between obesity-associated dysbiosis, chronic low-grade inflammation, and impaired appetite regulation through interconnected peripheral and central pathways. We discuss how these signals reach the central nervous system (CNS), and promote microglial and astrocytic activation, impair leptin and insulin signaling, and disrupt hypothalamic POMC and AgRP/NPY neuronal networks. We also examine how microbial metabolites and structural components influence appetite through enteroendocrine hormones, vagal afferents, blood-brain barrier (BBB) integrity, and direct actions on neural and glial cells. Particular emphasis is placed on short-chain fatty acids, tryptophan-derived metabolites, bile acids, and lipopolysaccharide, as well as their effects on glucagon-like peptide-1 (GLP-1), peptide YY (PYY), serotonergic signaling, and mesolimbic reward pathways. Together, these findings support a bidirectional framework in which diet, microbiota function, immune signaling, and neural regulation may reinforce one another during obesity progression. However, the directionality and causal relevance of many of these relationships, particularly in humans, remain incompletely understood. Clarifying these microbiota-gut-brain interactions may identify new targets for restoring appetite control and interrupting obesity progression.

PubMedFrontiers in medicine2026-10-17

AI-driven quality enhancement of medical datasets: a closed-loop framework of synthesis, annotation, quality control, and integration.

Tian Tao T, Zhang Siyuan S, Yang Xuchen X, Shi Rui R

The performance ceiling of medical AI is largely determined by the quality of its training datasets, yet traditional manual collection and annotation face a triple bottleneck of high cost, embedded bias, and limited scalability. This review takes "quality enhancement" as its unifying axis, integrating the four pillars of AI-driven medical dataset quality enhancement-synthetic data generation, intelligent annotation, automated quality control, and integration pipelines-and proposes a four-pillar integration framework as its core contribution. The framework organizes the four pillars into a closed loop: synthesis and annotation are coupled through dual-track feedback (a quantity track that replenishes data and a strategy track that adjusts generation strategy), while annotation and quality control are coupled through bidirectional verification. Beyond this forward enhancement loop, the framework further employs a bias amplification chain (as a heuristic insight) and the privacy-utility tradeoff as two tension lines, and incorporates Metrics Reloaded, FAIR, ALCOA+, and YY/T 1833 as sub-layer evaluation dimensions in a complementary manner. The review shows that AI-based enhancement methods have approached real data in statistical fidelity and downstream utility for select modalities, tasks, and evaluation settings, but systematic gaps remain in privacy, fairness, and clinical validity; single-pillar optimization is hypothesized, on the basis of indirect segmental evidence, to be insufficient to improve end-to-end quality, and closed-loop synergy is proposed as a testable proposition rather than an established requirement; integration pipelines are already usable for single-disease, single-modality settings, whereas cross-institutional, cross-modal, and cross-disease generalization remains the principal barrier, with federated construction and foundation-model-driven approaches as promising directions.

PubMedDiabetes, obesity & metabolism2026-10-15

Incorporation of Carob Into a High-Fat Meal Influences Subjective Satiety, Ghrelin and PYY Regulation.

Amerikanou Charalampia C, Kleftaki Stamatia-Angeliki SA, Tzavara Chara C, Vourtsi Aikaterini A et al.

Dietary components that influence appetite-related hormones and subjective satiety may help regulate food intake. Aqueous carob (Ceratonia siliqua L.) preparations may have a role in postprandial appetite regulation. To investigate the effects of an aqueous carob preparation incorporated into a high-fat meal on postprandial appetite-related hormones and subjective satiety. An acute randomized controlled crossover trial was conducted in 20 healthy males. Participants consumed two meals of similar energy content on separate occasions: a control meal containing an orange-flavoured beverage and a test meal containing an aqueous carob preparation. Blood samples and subjective appetite ratings, assessed using visual analogue scales, were collected over a 180-minute postprandial period. Compared with the control meal, the carob meal resulted in lower subjective hunger (p = 0.011) and desire to eat (p = 0.029), and greater satisfaction (p = 0.047). Peptide YY (PYY) area under the curve (AUC) values differed between meals (p = 0.040). Following the control meal, ghrelin decreased at 30 min (p = 0.012), followed by a marked increase at 180 min (p < 0.005). The magnitude of the change in ghrelin from baseline to 180 min differed between meal conditions (p = 0.005). The findings suggest that an aqueous carob preparation may improve subjective appetite responses when consumed with a high-fat meal. Differences in PYY and ghrelin responses may contribute to these effects, although a causal relationship was not established. The acute study design and inclusion of only healthy males limit conclusions about long-term effects and applicability to other populations. Incorporating an aqueous carob preparation into a high-fat meal may favourably influence postprandial appetite and satiety regulation. Further research is needed to determine whether these effects persist over time and translate into reduced food intake.

+4529 more articles available with a free account

Sign up free to view all articles →

Ask about YY-3130